MetaCap

Ionis Pharmaceuticals (IONS) vs Travere Therapeutics (TVTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Travere Therapeutics (TVTX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 35.5% versus a loss of 65.1%. Over five years, TVTX leads with a +61.9% price change compared with -8.5% for IONS. Travere Therapeutics is the larger company by market cap ($4.51 billion vs $4.43 billion), about 1.0 times the size.

Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -40.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IONS-65.07%TVTX+35.49%
+103%+15%-73%
Nov 21, 20251 yearNov 20, 2026
IONS-16.91%TVTX+60.57%
+183%+44%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IONS versus TVTX key metrics
MetricIONSTVTX
Share price$26.58$47.00
Market cap$4.43B$4.51B
1-day change-2.35%-2.69%
YTD return-66.40%+23.00%
1-year return-65.07%+35.49%
5-year return-8.50%+61.90%
Forward P/E—8.68
EPS (TTM)$-3.35$-1.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$943.71M$490.73M
Revenue growth (YoY)+33.83%+110.45%
Net income (latest FY)$-381.39M$-25.55M
Gross margin98.31%97.89%
Operating margin-40.45%-12.80%
Net margin-40.41%-5.21%
52-week high$86.74$68.73
52-week low$26.53$22.59
Distance from 52-week high-69.36%-31.62%
Analyst consensusbuystrong_buy
Avg. price target upside+155.19%+56.23%
Average volume3.91M1.81M
Shares outstanding166.55M95.99M
Employees1,485497
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TVTX has outperformed IONS by 100.6 percentage points over the past year.
  • Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -40.4 cents for Ionis Pharmaceuticals.
  • Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +33.83%).

About Ionis Pharmaceuticals

IONS stock →

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).

Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees

About Travere Therapeutics

TVTX stock →

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees

IONS vs TVTX FAQ

Which is bigger, Ionis Pharmaceuticals or Travere Therapeutics?

Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.51B compared with $4.43B for Ionis Pharmaceuticals (IONS).

Which stock has performed better over the past year, IONS or TVTX?

TVTX returned +35.49% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.

Are Ionis Pharmaceuticals and Travere Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons